Antiparasitic Drugs Market - By Drug Type (Anthelmintics, Antiprotozoal, Ectoparasiticide), Route of Administration (Injectable, Oral, Topical), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast (2024 - 2032)

Antiparasitic Drugs Market - By Drug Type (Anthelmintics, Antiprotozoal, Ectoparasiticide), Route of Administration (Injectable, Oral, Topical), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast (2024 - 2032)

Global Antiparasitic Drugs Market size will demonstrate 5.7% CAGR from 2024 to 2032, driven by their accessibility through nationwide distribution channels coupled with the diverse range of options. This widespread availability ensures that individuals in various regions can easily access essential medications for addressing the global burden of parasitic diseases more effectively. With a multitude of choices available, healthcare providers and patients have the flexibility to select the most suitable treatments, further contributing to the industry expansion. For instance, in March 2022, May & Baker Nigeria Plc. introduced Artelum Combo, a novel medication targeting malaria parasites, with a nationwide rollout aimed at addressing the country's malaria burden.

The antiparasitic drugs market is segmented on the basis of drug type, route of administration, end-user, and region.

Based on route of administration, the industry share from the oral segment will gain 6% CAGR up to 2032. The convenience and effectiveness of oral medications is making them a preferred choice for patients and healthcare providers. Oral formulations also offer ease of administration, improved patient compliance, and quicker absorption, leading to faster relief from parasitic infections. With rising advancements in oral drug delivery technologies and a wide range of oral antiparasitic options available, the need for oral solutions will grow for tackling global challenges posed by parasitic diseases.

In terms of end-user, the antiparasitic drugs market from the retail pharmacy segment will experience 6.2% CAGR through 2032, propelled by convenient access to medications for consumers coupled with the widespread presence of retail pharmacies in local communities. Of late, patients seeking antiparasitic remedies are turning to retail pharmacies for easy procurement and professional advice. Moreover, the rising trend of self-medication and over-the-counter sales will boost the preference for these pharmacies to render convenience and accessibility in addressing parasitic infections.

Asia Pacific antiparasitic drugs industry size will secure a 6.8% CAGR up to 2032, driven by rising incidences of parasitic infections, expanding healthcare infrastructure, and the increasing awareness about treatment options. Countries like China, India, and Japan are at the forefront, witnessing substantial demand for these medications. Additionally, there has been a rise in government initiatives aimed at eradicating parasitic diseases. With its diverse landscape and significant healthcare needs, the APAC region will emerge as a major contributor to the global antiparasitic drugs industry.